Biohaven Reports Positive Degrader Data Achieving > 80% Sustained Reductions in Total IgG with Potential First-in-Class BHV-1300
Biohaven Ltd. (NYSE: BHVN) ("Biohaven"), a global clinical-stage biopharmaceutical company focused on the discovery, ...
Clinical Trials Arena on MSN2d
Seismic Therapeutic doses first healthy participant cohort in Phase I trial of S-1117
US-based biotechnology company Seismic Therapeutic has dosed the initial cohort of healthy participants in a randomised Phase ...
Nature2mon
Isotype selection in antibody engineering
The properties of the different IgG isotypes should be considered in ... shows no preference for the original or a different half-molecule and is driven by the relative amounts of both parent ...
Biohaven reports ‘positive’ data from study of BHV-1300
Biohaven (BHVN) highlighted the success of BHV-1300, its potential first-in-class IgG selective degrader, in achieving rapid and deep ...
Medscape5d
Hepatitis A Virus: Serology and Molecular Diagnostics
Molecular diagnosis of HAV along with anti-HAV IgG avidity measurement are helpful in case of positive IgM where laboratory evidence of acute hepatitis is absent and there is no epidemiologic link ...
Biohaven Reports Recent Business Developments and Fourth Quarter and Full Year 2024 Financial Results
Biohaven Ltd. (NYSE: BHVN) (Biohaven or the Company), a global clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of life-changing therapies to treat ...
Biohaven Ltd.: Biohaven Reports Positive Degrader Data Achieving > 80% Sustained Reductions in Total IgG with Potential First-in-Class BHV-1300
Optimized subcutaneous administration of BHV-1300 achieved rapid, deep and sustained lowering of IgG, differentiating Biohaven's new small molecule class of degraders from the monoclonal ...